ArticleCancer immunology, immunotherapy : CII2023

Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic leukemia.

Yutaka Shimazu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.